Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Centre, Single-Arm Study on the Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis

NCT07502105 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07502105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07502105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Centre, Single-Arm Study on the Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
Lead sponsor
Tongji Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
December 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic scleroderma